High frequency of genetic alterations of tumor suppressors (e.g., PTEN and CDKN2A/CDKN2B) and oncogenes (e.g., PDGFA and EGFR) suggested that these cancer driver genes might be responsible for initiation of mGBM but not contribute to the progression of mGBM. This evidence concerns the gene CDKN2B and cancer.